Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). (Q39883799)

15 September 2017

title

Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). (English)

1 reference

15 September 2017

0 references

1

1 reference

15 September 2017

3

1 reference

15 September 2017

12

1 reference

15 September 2017

author name string

Maria Antonietta Medici

2

1 reference

15 September 2017

Maria Teresa Sciortino

4

1 reference

15 September 2017

Francesca Marino Merlo

5

1 reference

15 September 2017

Susanna Campo

6

1 reference

15 September 2017

Valentina Donato

7

1 reference

15 September 2017

Assunta Venuti

8

1 reference

15 September 2017

Alessio Sturiale

9

1 reference

15 September 2017

Daniela Zaccaria

10

1 reference

15 September 2017

Antoine Buemi

11

1 reference

15 September 2017

Michele Buemi

13

1 reference

15 September 2017

publication date

14 February 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

28

1 reference

15 September 2017

issue

6

1 reference

15 September 2017

page(s)

642-647

1 reference

15 September 2017

cites work

Vasopressin receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Gene regulation of vasopressin and vasopressin receptors in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

The vasopressin system: physiology and clinical strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Epidemiologic aspects of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Erythropoietin stimulates proliferation of human renal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Prognostic significance of erythropoietin expression in human renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

New approaches to the therapy of various tumors based on peptide analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Renal cystic neoplasms and renal neoplasms associated with cystic renal diseases: pathogenetic and molecular links

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Bilateral renal cell carcinoma in autosomal dominant polycystic kidney disease. A case report and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

Aquaretic agents: what's beyond the treatment of hyponatremia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.12.014

10.1016/J.UROLONC.2008.12.014

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference